JP4697679B2 - Ｈｉｖインテグラーゼの阻害剤としてのキノリン誘導体 - Google Patents

Ｈｉｖインテグラーゼの阻害剤としてのキノリン誘導体 Download PDF

Info

Publication number
JP4697679B2
JP4697679B2 JP54245998A JP54245998A JP4697679B2 JP 4697679 B2 JP4697679 B2 JP 4697679B2 JP 54245998 A JP54245998 A JP 54245998A JP 54245998 A JP54245998 A JP 54245998A JP 4697679 B2 JP4697679 B2 JP 4697679B2
Authority
JP
Japan
Prior art keywords
ethenyl
hydroxy
group
formula
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP54245998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001518890A (ja
JP2001518890A5 (https=
Inventor
カリド メクア
ジャン ダーンジュロ
ディディエ デスマール
ジャン フランソワ ムスカデ
フレデリック シブラ
クリスチャン オクレール
Original Assignee
サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク セエンエールエス
アンスティテュ ギュスターブ ルシィ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク セエンエールエス, アンスティテュ ギュスターブ ルシィ filed Critical サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク セエンエールエス
Publication of JP2001518890A publication Critical patent/JP2001518890A/ja
Publication of JP2001518890A5 publication Critical patent/JP2001518890A5/ja
Application granted granted Critical
Publication of JP4697679B2 publication Critical patent/JP4697679B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP54245998A 1997-04-08 1998-04-07 Ｈｉｖインテグラーゼの阻害剤としてのキノリン誘導体 Expired - Fee Related JP4697679B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9704289A FR2761687B1 (fr) 1997-04-08 1997-04-08 Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
FR97/04289 1997-04-08
PCT/FR1998/000701 WO1998045269A1 (fr) 1997-04-08 1998-04-07 Derives de quinoleines en tant qu'inhibiteurs de la vih integrase

Publications (3)

Publication Number Publication Date
JP2001518890A JP2001518890A (ja) 2001-10-16
JP2001518890A5 JP2001518890A5 (https=) 2005-11-10
JP4697679B2 true JP4697679B2 (ja) 2011-06-08

Family

ID=9505648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54245998A Expired - Fee Related JP4697679B2 (ja) 1997-04-08 1998-04-07 Ｈｉｖインテグラーゼの阻害剤としてのキノリン誘導体

Country Status (12)

Country Link
US (1) US6670377B1 (https=)
EP (1) EP0975597B1 (https=)
JP (1) JP4697679B2 (https=)
AT (1) ATE441634T1 (https=)
CA (1) CA2286385C (https=)
CY (1) CY1109553T1 (https=)
DE (1) DE69841119D1 (https=)
DK (1) DK0975597T3 (https=)
ES (1) ES2332434T3 (https=)
FR (1) FR2761687B1 (https=)
PT (1) PT975597E (https=)
WO (1) WO1998045269A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2321348A1 (en) * 2000-09-27 2002-03-27 Blaise Magloire N'zemba Aromatic derivatives with hiv integrase inhibitory properties
FR2819507B1 (fr) 2001-01-17 2007-09-28 Inst Rech Developpement Ird Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus
JP3616628B2 (ja) 2001-03-01 2005-02-02 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する含窒素芳香族複素環化合物
FR2830863B1 (fr) * 2001-10-12 2004-01-30 Bioalliance Pharma Derives de quinoleine, procede de synthese, et medicaments renfermant ces derives
FR2839646B1 (fr) * 2002-05-17 2008-04-11 Bioalliance Pharma Utilisation de derives de quinoleine a effet anti-integrase et ses applications
EP1541558B1 (en) 2002-08-13 2008-08-13 Shionogi & Co., Ltd. Heterocyclic compounds having hiv integrase inhibitory activity
EP2161258A3 (en) 2002-11-20 2010-04-07 Japan Tabacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
RU2275361C3 (ru) * 2002-11-20 2021-10-01 Джапан Тобакко Инк. Соединение 4-оксохинолина и его применение в качестве ингибитора вич интегразы
KR100866296B1 (ko) * 2004-05-20 2008-11-11 니뽄 다바코 산교 가부시키가이샤 ４―옥소퀴놀린 화합물의 안정한 결정체
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
US20080280849A1 (en) * 2005-06-01 2008-11-13 Herve Leh Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents
RS54047B1 (sr) 2006-03-06 2015-10-30 Japan Tobacco Inc. Postupak za dobijanje jedinjenja 4-oksohinolina
EP2520561B1 (en) * 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
CA2705318C (en) * 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
AU2008323561B2 (en) * 2007-11-15 2013-07-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
MX2010005334A (es) 2007-11-16 2010-05-27 Boehringer Ingelheim Int Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
JP5269087B2 (ja) * 2007-11-16 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルス複製のインヒビター
EP2147912A1 (en) 2008-07-23 2010-01-27 BioAlliance Pharma Styrylquinolines, their process of preparation and their therapeutic uses
EP2147913A1 (en) * 2008-07-23 2010-01-27 BioAlliance Pharma Styrylquinolines, their process of preparation and their therapeutic uses
EP2149557A1 (en) 2008-07-23 2010-02-03 BioAlliance Pharma Styrylquinolines, their process of preparation and their therapeutic uses
KR20130124291A (ko) * 2010-07-02 2013-11-13 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 항바이러스 화합물로서의 2-퀴놀리닐-아세트산 유도체
CA2860015C (en) 2011-12-22 2020-07-07 Universite Laval Three-dimensional cavities of dendritic cell immunoreceptor (dcir), compounds binding thereto and therapeutic applications related to inhibition of human immunodeficiency virus type-1 (hiv-1)
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
JP7542538B2 (ja) 2018-09-18 2024-08-30 ニカング セラピューティクス， インコーポレイテッド Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59152891A (ja) * 1983-02-18 1984-08-31 Yamada Kagaku Kogyo Kk 発色性記録材料
IE861607L (en) * 1985-06-18 1986-12-18 Bunce Roger A 2-substituted quinolines
EP0219307A3 (en) * 1985-10-16 1987-10-14 Merck Frosst Canada Inc. 2-substituted quinolines
JPS61189988A (ja) * 1986-08-11 1986-08-23 Yamada Kagaku Kogyo Kk 発色性記録材料
JPH01199979A (ja) 1987-04-07 1989-08-11 Kanebo Ltd 新規キノリンカルボン酸誘導体および該化合物を有効成分とする抗菌剤
IL88433A0 (en) 1987-11-25 1989-06-30 Merck Frosst Canada Inc Diarylstyrylquinoline diacids and pharmaceutical compositions containing them
US5438141A (en) * 1993-05-21 1995-08-01 Merck Frosst Canada, Inc. Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid as leukotriene antagonists
EP0643045B1 (de) * 1993-09-10 2000-03-08 Novartis AG Chinolin-Verbindungen als Leukotriene Antagonisten
GB9414590D0 (en) * 1994-07-20 1994-09-07 Leo Pharm Prod Ltd Chemical compounds
ES2103180B1 (es) * 1994-08-01 1998-04-01 Menarini Lab Fenilacetamidas con accion antagonista de los leucotrienos.
EP0725063A1 (de) * 1995-02-01 1996-08-07 Ciba-Geigy Ag Chinolin-Derivate
EP0927164A1 (en) * 1996-09-10 1999-07-07 PHARMACIA & UPJOHN COMPANY 8-hydroxy-7-substituted quinolines as anti-viral agents

Also Published As

Publication number Publication date
CY1109553T1 (el) 2014-08-13
DK0975597T3 (da) 2009-11-02
ES2332434T3 (es) 2010-02-04
FR2761687A1 (fr) 1998-10-09
US6670377B1 (en) 2003-12-30
FR2761687B1 (fr) 2000-09-15
JP2001518890A (ja) 2001-10-16
PT975597E (pt) 2010-01-04
WO1998045269A1 (fr) 1998-10-15
DE69841119D1 (de) 2009-10-15
CA2286385A1 (fr) 1998-10-15
ATE441634T1 (de) 2009-09-15
EP0975597B1 (fr) 2009-09-02
EP0975597A1 (fr) 2000-02-02
CA2286385C (fr) 2011-02-01

Similar Documents

Publication Publication Date Title
JP4697679B2 (ja) Ｈｉｖインテグラーゼの阻害剤としてのキノリン誘導体
JPH01279866A (ja) キノリン系メバロノラクトン類
JPH06759B2 (ja) 新規なベンゾイミダゾール化合物
CS390691A3 (en) Olefinic 1h-imidazo-(4,5-c)quinolin-4-amines
JPH07501816A (ja) Ｈｉｖに対する医薬組成物
EA003272B1 (ru) Производные дигидро- и тетрагидрохинолина, способ их получения и содержащие их фармацевтические составы
JP2000080087A (ja) 新規ベンゾオキサゾ―ル類
WO2010010149A1 (en) Styrylquinolines, their process of preparation and their therapeutic uses
JPH0383979A (ja) 新規ベンゾピランおよびベンゾチオピラン誘導体
ES2236288T3 (es) 6-heteroarilfenantridinas.
JP3140494B2 (ja) 置換されたフエニルアセチレン、これを含有する薬剤、この化合物及び薬剤を製造する方法
FR2722195A1 (fr) Nouveaux derives de 1,3-dihydro-2h-pyrrolo(2,3-b) pyridin-2-ones et oxazolo(4,5-b) pyridin-2(3h)-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN116924959B (zh) 一种hdac11亚型选择性抑制剂及其制备方法和应用
JPH0374370A (ja) ピラジン誘導体およびこれを含有する血小板凝集抑制剤または抗炎症剤
US7064133B2 (en) Quinoline derivatives process of synthesis and medicaments containing these derivatives
CN105315204B (zh) 7‑氨基‑1,4‑二氢异喹啉‑3(2h)‑酮衍生物及其合成方法和用途
CN110872263B (zh) 一种化合物以及制备方法和应用
JPH04253975A (ja) Ｈｉｖ逆転写酵素阻害物質
JPS6212757A (ja) 桂皮酸アミド誘導体
EP2149557A1 (en) Styrylquinolines, their process of preparation and their therapeutic uses
CN115160281A (zh) 一种异香豆素类衍生物衍生物及其在抗疟药物中的应用
JPH0753554A (ja) クマリン誘導体及びそれらの用途
JPS6160832B2 (https=)
EP2147912A1 (en) Styrylquinolines, their process of preparation and their therapeutic uses
JP4638736B2 (ja) 新規のベンゾナフチリジン

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090306

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090409

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100115

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101216

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110221

LAPS Cancellation because of no payment of annual fees